Physician profile
Michael E Jones
NPI 1407881881
$17,955.07
in general payments reported to CMS, 2019-2025
59 companies · $2,338 in 2025
The $2,338 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,336 · 2020: $2,140 · 2021: $2,651 · 2022: $2,939 · 2023: $2,813 · 2024: $2,740 · 2025: $2,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,890.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,918.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,224.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,587.75 | 2019-2025 | Mounjaro, Emgality, Reyvow |
| Abbvie INC. | $1,410.30 | 2019-2024 | |
| Amgen INC. | $799.40 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.66 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $725.12 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $669.85 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $527.60 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $452.68 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $425.58 | 2019-2023 | Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $421.73 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $408.23 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $399.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $334.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.